CoChat

Targeted Nalmefene With Simple Medical Management in the Treatment of Heavy Drinkers: A Randomized Double‐Blind Placebo‐Controlled Multicenter Study

Karhuvaara, Sakari, Simojoki, Kaarlo, Virta, Antti, Rosberg, Markus, Löyttyniemi, Eliisa, Nurminen, Tommi, Kallio, Antero, Mäkelä, Rauno · 2007 · Alcoholism: Clinical and Experimental Research
Cited by 128

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

Background: Clinical studies with opioid antagonists for treatment of problem drinking have mainly been conducted in specialized alcohol treatment centers, included structured psychosocial treatment, and have focused on maintaining abstinence after a period of abstinence from alcohol. Methods: This multisite, randomized double‐blind study investigated targeted nalmefene in reducing heavy drinking. Specialized alcohol treatment centers and private general practices enrolled 403 subjects (328 men, 75 women). Subjects were instructed to take nalmefene 10 to 40 mg (n=242) or placebo (n=161) when they believed drinking to be imminent. After 28 weeks, 57 subjects from the nalmefene group continued into a 24‐week randomized withdrawal extension. Concomitant psychosocial intervention was minimal and no treatment goals were imposed. Alcohol consumption was recorded using the time‐line follow‐back method. Biochemical indicators of alcohol use were also measured. Results: The mean monthly number of heavy drinking days (HDDs) during the 12‐week period before inclusion was 15.5 (SD 6.9) in the nalmefene group and 16.2 (SD 6.9) in the placebo group. During treatment, the mean numbers of HDDs were 8.6 to 9.3 in the nalmefene group and 10.6 to 12.0 in the placebo group (p=0.0065). The levels of serum alanine aminotransferase and γ‐glutamyl transferase decreased in the nalmefene group compared with the placebo group (p=0.0088 and 0.0023). During the randomized withdrawal period, subjects randomized to placebo apparently returned to heavier drinking. Subjects receiving nalmefene reported more nausea, insomnia, fatigue, dizziness, and malaise than subjects on placebo. Conclusions: Nalmefene appears to be effective and safe in reducing heavy drinking, even when accompanied by minimal psychosocial support.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1530-0277.2007.00401.x

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 128

Metadata

Authors
Karhuvaara, S., Simojoki, K., Virta, A., Rosberg, M., Löyttyniemi, E., Nurminen, T., Kallio, A., & Mäkelä, R.
Venue
Alcoholism: Clinical and Experimental Research
Publisher
Wiley
Published
2007-04-19
Volume
31
Issue
7
Pages
1179-1187
ISSN
  • 0145-6008 (ISSN-L)
  • 1530-0277
OpenAlex
W2038442697
Cited by
128
References
3
FWCI
3.14
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Targeted Nalmefene With Simple Medical Management in the Treatment of Heavy Drinkers: A Randomized Double‐Blind Placebo‐Controlled Multicenter Study. https://app.cochat.ai/papers/10.1111/j.1530-0277.2007.00401.x
The paper
Karhuvaara, S., Simojoki, K., Virta, A., Rosberg, M., Löyttyniemi, E., Nurminen, T., Kallio, A., & Mäkelä, R. (2007). Targeted Nalmefene With Simple Medical Management in the Treatment of Heavy Drinkers: A Randomized Double‐Blind Placebo‐Controlled Multicenter Study. Alcoholism: Clinical and Experimental Research. https://doi.org/10.1111/j.1530-0277.2007.00401.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.